공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

인공 혈관 시장 : 예측(2021-2026년)

Vascular Graft Market - Forecasts from 2021 to 2026

리서치사 Knowledge Sourcing Intelligence
발행일 2021년 10월 상품 코드 1023201
페이지 정보 영문 118 Pages
가격
US $ 3,950 ₩ 4,713,000 PDF (Single User License)
US $ 4,550 ₩ 5,429,000 PDF (Multiple User License)
US $ 6,950 ₩ 8,294,000 PDF (Enterprise License)


인공 혈관 시장 : 예측(2021-2026년) Vascular Graft Market - Forecasts from 2021 to 2026
발행일 : 2021년 10월 페이지 정보 : 영문 118 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계 인공 혈관 시장 규모는 2019년의 56억 3,700만 달러에서 2026년에는 79억 5,500만 달러를 기록할 것으로 보여지며, 예측 기간 동안 5.04%의 CAGR로 성장할 것으로 예상 됩니다.

인공 혈관은 감염되거나 손상된 정맥을 신중하게 치료하고, 혈관을 복구하여 혈류를 재구축하는 유의한 기술입니다. 튼튼한 혈관을 이상적으로 복구하는 것은 미래 발전을 약속할 수 있습니다. 이로 인해 내성이 있는 건강을 더욱 자유롭게 선택할 기회가 생깁니다.

심혈관 감염, 신부전, 정맥 질환 환자의 증가, 세계적인 노인 인구의 증가, 예방 의료에 대한 공공 기관의 관심 증가, 건실한 미래에 대한 중요성, 의료 서비스 관리에 액세스 하기 위한 다이렉트 투 쇼퍼 접근 방식의 채택 확대 등은, 2021년부터 2028년까지의 예측 기간에 인공 혈관 시장의 발전을 촉진시킬 수 있는 중요 요소입니다. 또한 진단 활동의 확대, 분리 정밀도 향상, 맞춤형 약물의 사용 등 높은 자유도가 향후 수년간 인공 혈관 시장의 발전을 촉진 것입니다.

그러나 다양한 기업이 제공하는 이식 비용이 불안정하기 때문에, 검사의 수송 문제가 확대되고 있는 점은, 예측 기간 동안 인공 혈관 시장의 발전을 제한하는 요인이 될 가능성이 있습니다. 상환 전략의 부재 역시 시장 발전을 위한 가장 크고 중요한 시험이 될 것입니다.

세계 인공 혈관(Vascular Graft) 시장을 조사했으며, 시장 개요 및 동향/기업 간의 경쟁 상황/소재별·적응증별·지역별 시장 분석 등의 정보를 제공합니다.

목차

제1장 서론

  • 시장 정의
  • 시장 세분화

제2장 조사 방법

  • 조사 데이터
  • 가정

제3장 개요

  • 조사의 하이라이트

제4장 시장 역학

  • 시장의 추진력
  • 시장 저해 요인
  • 포터의 5세력 모형
    • 공급 기업의 경쟁력
    • 구매 기업의 경쟁력
    • 신규 진입 업체의 위협
    • 대체품의 위협
    • 기능의 경쟁 기업 간의 경쟁 관계
  • 기능 가치 사슬 분석

제5장 소재별 : 인공 혈관 시장 분석

  • 서론
  • 인공
  • 하이브리드
  • 생체 소재

제6장 적응증별 : 인공 혈관 시장 분석

  • 서론
  • 심혈관 질환
  • 신장 질환
  • 동맥류
  • 기타

제7장 최종 사용자별 : 인공 혈관 시장 분석

  • 서론
  • 병원과 클리닉
  • 외래 수술 센터

제8장 지역별 : 인공 혈관 시장 분석

  • 서론
  • 북미
    • 미국
    • 캐나다
    • 멕시코
  • 남미
    • 브라질
    • 아르헨티나
    • 기타
  • 유럽
    • 영국
    • 독일
    • 이탈리아
    • 스페인
    • 기타
  • 중동과 아프리카
    • 이스라엘
    • 사우디아라비아
    • 기타
  • 아시아 태평양
    • 중국
    • 일본
    • 인도
    • 호주
    • 한국
    • 대만
    • 태국
    • 인도네시아
    • 기타

제9장 경쟁 환경 분석

  • 주요 기업과 전략 분석
  • 신생 기업과 시장의 수익성
  • 합병, 인수, 합의, 공동 연구
  • 공급 업체 경쟁력 매트릭스

제10장 기업 개요

  • Hancock Jaffe Laboratories, Inc.
  • Getinge Group
  • WL Gore&Associates
  • Vascular Flow Technologies
  • CR Bard, Inc.
  • Artegraft Inc.
  • Vascular Genesis
  • B. Braun Melsungen AG
  • LeMaitre Vascular, Inc.
  • Terumo Aortic
LYJ 21.09.07

The global vascular graft market is projected to grow at a CAGR of 5.04% to reach US$7.955 billion by 2026, from US$5.637 billion in 2019

A vascular graft is a surgical technique that reconnects blood arteries to shift blood flow from one part of the body to another. The most common reason for vascular grafting is to increase blood flow to an organ fed by a damaged artery by bypassing a total or partial obstruction. These grafts range in size from 5-8 mm in diameter. This allows the body's blood flow to return to normal. Catheter-based devices are inserted through a small incision and guided with the use of real-time imaging technology in vascular transplant surgeries. Development of efficient and advanced novel products using tissue-engineered and biological materials, increased public awareness of peripheral artery diseases and coronary diseases, increased government initiatives around the world propel the global vascular graft market during the forecast period. The major growth drivers of the vascular graft market are the growing incidence of cardiovascular illnesses such as hypertension, coronary artery disease, and cardiac aneurysms, as well as the rising prevalence of diabetes. Moreover, increased vascular graft usage in emerging nations such as China, India, and others would open up new potential for the vascular graft market.

The vascular graft market growth is anticipated to be further aided by the rise in the senior population, technological improvements, and changes in lifestyle (consumption of junk food, cigarettes, and alcohol). The growing prevalence of end-stage renal diseases (ESRD) has further boosted the demand for vascular grafting during the forecast period. Dialysis, which is often used by individuals with ESRD, is the sole option for kidney transplantation. Three times a week, hemodialysis is performed. Many patients' superficial veins have been depleted as a result of continuous dialysis, and vascular grafts are the only way to continue hemodialysis. In 2017, 124,500 new cases of ESRD were reported in the United States, with a crude (uncorrected) incidence rate of 370.2 per million per year. The number of people living with ESRD is increasing at a rate of around 20,000 each year.

Due to strong medical reimbursement facilities and technical advancements, North America has anticipated led the vascular graft industry. Due to a rapidly growing geriatric population, increased consumer awareness, increased healthcare expenditure, favorable government policies, modernization of healthcare infrastructure, and growing medical tourism industry in developing countries such as China and India in this region, Asia Pacific is expected to grow at the fastest rate. The increased incidence of CKD, healthcare reforms, government efforts and investments, and rapid growth in the elderly population are all contributing to the Asia Pacific market's expanding growth. In addition, emerging markets such as Australia, Singapore, Japan provide various development possibilities for vascular grafts market participants because of an aging population and an increase in end-stage renal disease.

Growth Factors

The growing requirement for hemodialysis will fuel demand for vascular grafts

One of the major reasons for the growth of the global vascular graft market is the growing demand for hemodialysis. The growing need for hemodialysis products will boost demand for vascular grafts and propel the sector forward. Dialysis operations will become more common as the number of people with end-stage renal illness rises, as will the number of people with chronic kidney disease. Hemodialysis patients also require a well-functioning arteriovenous graft for a successful hemodialysis operation. According to research from the National Renal Foundation, 785,883 Americans suffered kidney failure in 2018 and required dialysis or a kidney transplant to live. As a result, the rising prevalence of chronic renal disease will lead to an increase in the number of hemodialysis procedures. Cook Medical's Zenith fenestrated endovascular graft earned FDA breakthrough device designation in March 2021. For life-threatening or profoundly disabling diseases or conditions, the product delivers more effective therapy or diagnosis. This strategy is anticipated to add value to the company's current portfolio while also generating money through sales. Furthermore, the increasing prevalence of cardiovascular illnesses throughout the world will drive up demand for vascular grafts.

Restraints

Product recalls and failures to hinder the market growth during the forecast period.

A major restraint in the growth of the global vascular graft market is the product recalls and failures limiting the adoption of vascular graft during the forecast period. Patients might suffer serious or even fatal consequences as a result of product failures. Several businesses' goods have been recalled from the market throughout the years owing to product faults or other concerns. End-user perceptions of graft safety may be harmed as a result of market trends, which may influence their acceptance in treatment processes. As a result, the adoption of vascular grafts has been restrained during the forecast period.

COVID-19 Impact

The COVID-19 pandemic has had a great impact on the world as a whole and has led to economic breakdown and loss of life. Production activities are interrupted because of lockdown measures enforced in numerous countries. The COVID-19 impact on the global vascular graft market has been adverse owing to the production halt by industries due to the temporary lockdown implemented by several governments to break the cycle of the virus. The disruption in the demand and supply chain has further hampered the market in the forecast period. Despite the availability of OPD administrations at emergency clinics, the number of patient visits to clinics has fallen significantly in recent months. Despite this, patient visits to medical facilities have fallen significantly as a result of the lockdown in several countries. As a result, the number of suggestive tests has decreased. The sale of vascular grafts has also decreased as a result of this. Since the majority of vascular grafts and interventional techniques are elective, many of these procedures have been postponed. This is another issue that has a negative impact on the market for vascular grafts. However, in the post-COVID-19 scenario, the global vascular graft market is expected to boom with the increasing demand during the forecast period.

Competitive Insights

The market leaders for the pretreatment coating market are Hancock Jaffe Laboratories Inc., Getinge Group, W.L. Gore & Associates, Vascular Flow Technologies, C.R. Bard Inc., Artegraft Inc., Vascular Genesis, B. Braun Melsungen AG, LeMaitre Vascular Inc., and Terumo Aortic.

Segmentation:

By Source

  • Synthetic
  • Semi-Synthetic
  • Natural

By Indication

  • Cardiovascular Diseases
  • Renal Diseases
  • Aneurysms
  • Others

By End-Users

  • Hospitals and Clinics
  • Ambulatory Surgical Centers

By Geography

  • North America
    • USA
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • UK
    • Germany
    • France
    • Spain
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • Israel
    • Others
  • Asia Pacific
    • Japan
    • China
    • India
    • Indonesia
    • Taiwan
    • Thailand
    • Others

Table of Contents

1. Introduction

  • 1.1. Market Definition
  • 1.2. Market Segmentation

2. Research Methodology

  • 2.1. Research Data
  • 2.2. Assumptions

3. Executive Summary

  • 3.1. Research Highlights

4. Market Dynamics

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porters Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. The threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. Vascular Graft Market Analysis, By Source

  • 5.1. Introduction
  • 5.2. Synthetic
  • 5.3. Semi-Synthetic
  • 5.4. Natural

6. Vascular Graft Market Analysis, By Indication

  • 6.1. Introduction
  • 6.2. Cardiovascular Diseases
  • 6.3. Renal Diseases
  • 6.4. Aneurysms
  • 6.5. Others

7. Vascular Graft Market Analysis, By End-User

  • 7.1. Introduction
  • 7.2. Hospitals & Clinics
  • 7.3. Ambulatory Surgical Centers

8. Vascular Graft Market Analysis, By Geography

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. United States
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. UK
    • 8.4.2. France
    • 8.4.3. Germany
    • 8.4.4. Italy
    • 8.4.5. Others
  • 8.5. Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. Israel
    • 8.5.3. Others
  • 8.6. Asia Pacific
    • 8.6.1. Japan
    • 8.6.2. China
    • 8.6.3. India
    • 8.6.4. Australia
    • 8.6.5. South Korea
    • 8.6.6. Thailand
    • 8.6.7. Taiwan
    • 8.6.8. Indonesia
    • 8.6.9. Others

9. Competitive Environment and Analysis

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Emerging Players and Market Lucrativeness
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Vendor Competitiveness Matrix

10. Company Profiles

  • 10.1. Hancock Jaffe Laboratories Inc.
  • 10.2. Getinge Group
  • 10.3. W.L. Gore & Associates
  • 10.4. Vascular Flow Technologies
  • 10.5. C.R. Bard Inc.
  • 10.6. Artegraft Inc.
  • 10.7. Vascular Genesis
  • 10.8. B. Braun Melsungen AG
  • 10.9. LeMaitre Vascular Inc.
  • 10.10. Terumo Aortic
Back to Top
전화 문의
F A Q